Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2025 16:01 ET | Source: Opus Genetics, Inc.

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 03, 2025 08:00 ET | Source: Opus Genetics, Inc.

Opus Genetics Featured on Good Morning America Spotlighting Breakthrough Gene Therapy Restoring Sight in Patients with Inherited Blindness

Opus Genetics Featured on Good Morning America Spotlighting Breakthrough Gene Therapy Restoring Sight in Patients with Inherited Blindness
October 14, 2025 08:00 ET | Source: Opus Genetics, Inc.

Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference

Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference
October 02, 2025 08:00 ET | Source: Opus Genetics, Inc.

Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025

Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025
September 30, 2025 07:00 ET | Source: Opus Genetics, Inc.

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
September 12, 2025 08:00 ET | Source: Opus Genetics, Inc.

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2025 08:00 ET | Source: Opus Genetics, Inc.

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Visual Disturbances
September 03, 2025 08:00 ET | Source: Opus Genetics, Inc.

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
September 02, 2025 08:00 ET | Source: Opus Genetics, Inc.

Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

Opus Genetics Appoints Rob Gagnon as Chief Financial Officer
August 27, 2025 08:00 ET | Source: Opus Genetics, Inc.

Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September

Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September